Literature DB >> 23273162

A new combination therapy for asthma: bridging the gap between effectiveness in trials and clinical practice?

Alberto Papi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23273162     DOI： 10.1016/S0954-6111(12)00462-3

Source DB:  PubMed          Journal:  Respir Med        ISSN： 0954-6111            Impact factor:   3.415


× No keyword cloud information.
  2 in total

1.  Neuroimmune semaphorin 4A as a drug and drug target for asthma.

Authors:  G Mogie; K Shanks; E H Nkyimbeng-Takwi; E Smith; E Davila; M M Lipsky; L J DeTolla; A D Keegan; S P Chapoval
Journal:  Int Immunopharmacol       Date:  2013-08-28       Impact factor: 4.932

2.  Severe asthma treatment patterns: A multicenter observational study in the Gulf region.

Authors:  Mona Al-Ahmad; Hassan Mobayed; Nasser Al Busaidi; Mohamed Nizam Iqbal; Saif Al Mubaihsi; Moussa Khadadah; Abeer Kassem; Mohamed Abuzakouk; Mateen Uzbeck; Ashraf Al Zaabi; Hisham Farouk
Journal:  World Allergy Organ J       Date:  2022-05-19       Impact factor: 5.516
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.